Raltegravir  	Raltegravir  	 JJ	B-NP
use  	use  	 NN	I-NP
in  	in  	 IN	O
special  	special  	 JJ	O
populations  	populations  	 JJ	O
Raltegravir 	Raltegravir 	 NNP	B-NP
,  	,  	 ,	O
the  	the  	 DT	O
first  	first  	 JJ	O
approved  	approved  	 VBN	O
integrase  	integrase  	 JJ	B-NP
inhibitor 	inhibitor 	 NN	I-NP
,  	,  	 ,	O
has  	has  	 VBZ	O
been  	been  	 VBN	O
shown  	shown  	 VBN	O
to  	to  	 TO	O
be  	be  	 VB	O
virologically  	virologically  	 JJ	O
effective  	effective  	 JJ	O
in  	in  	 IN	O
Phase  	Phase  	 NNP	O
II  	II  	 NNP	O
and  	and  	 CC	O
Phase  	Phase  	 NNP	O
III  	III  	 NNP	O
clinical  	clinical  	 JJ	B-NP
trials  	trials  	 NNS	I-NP
in  	in  	 IN	O
both  	both  	 DT	O
treatment  	treatment  	 NN	O
naive  	naive  	 NNS	O
and  	and  	 CC	O
triple  	triple  	 JJ	O
class  	class  	 NN	O
resistant  	resistant  	 JJ	O
patients 	patients 	 NNS	O
.  	.  	 .	O
It  	It  	 PRP	O
also  	also  	 RB	O
has  	has  	 VBZ	O
an  	an  	 DT	O
excellent  	excellent  	 JJ	O
tolerability  	tolerability  	 JJ	B-NP
profile  	profile  	 NN	I-NP
and  	and  	 CC	O
lacks  	lacks  	 VBZ	O
significant  	significant  	 JJ	O
drug-drug  	drug-drug  	 JJ	B-NP
interactions  	interactions  	 NNS	I-NP
making  	making  	 VBG	O
it  	it  	 PRP	O
an  	an  	 DT	O
important  	important  	 JJ	O
drug  	drug  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
a  	a  	 DT	O
number  	number  	 NN	O
of  	of  	 IN	O
special  	special  	 JJ	O
patient  	patient  	 NN	O
populations 	populations 	 NNS	O
.  	.  	 .	O
In  	In  	 IN	O
this  	this  	 DT	O
review  	review  	 NN	O
its  	its  	 PRP$	O
use  	use  	 NN	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
undergoing  	undergoing  	 VBG	O
solid  	solid  	 JJ	O
organ  	organ  	 NN	B-NP
and  	and  	 CC	O
bone  	bone  	 JJ	B-NP
marrow  	marrow  	 JJ	I-NP
transplantation  	transplantation  	 NN	I-NP
and  	and  	 CC	O
patients  	patients  	 NNS	O
receiving  	receiving  	 VBG	B-NP
cancer  	cancer  	 NN	I-NP
chemotherapy 	chemotherapy 	 NN	I-NP
,  	,  	 ,	O
will  	will  	 MD	O
be  	be  	 VB	O
discussed 	discussed 	 VBN	O
.  	.  	 .	O
In  	In  	 IN	O
addition  	addition  	 NN	B-NP
other  	other  	 JJ	O
indications  	indications  	 NNS	O
including  	including  	 VBG	B-NP
patients  	patients  	 NNS	I-NP
with  	with  	 IN	O
metabolic  	metabolic  	 JJ	B-NP
complications  	complications  	 NNS	I-NP
of  	of  	 IN	O
existing  	existing  	 VBG	O
antiretroviral  	antiretroviral  	 JJ	B-NP
drugs  	drugs  	 NNS	I-NP
as  	as  	 IN	O
well  	well  	 RB	O
as  	as  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
side  	side  	 NN	B-NP
effects  	effects  	 NNS	I-NP
on  	on  	 IN	O
current  	current  	 JJ	O
HAART  	HAART  	 NNP	B-NP
regimens 	regimens 	 NN	I-NP
.  	.  	 .	O
Other  	Other  	 JJ	O
groups  	groups  	 NNS	O
of  	of  	 IN	O
patients  	patients  	 NNS	O
where  	where  	 WRB	O
raltegravir  	raltegravir  	 NNS	B-NP
may  	may  	 MD	O
play  	play  	 VB	O
an  	an  	 DT	O
important  	important  	 JJ	O
role  	role  	 NN	O
are  	are  	 VBP	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
renal  	renal  	 JJ	B-NP
disease  	disease  	 NN	I-NP
and  	and  	 CC	O
tuberculosis 	tuberculosis 	 NN	O
.  	.  	 .	O
Finally 	Finally 	 RB	O
,  	,  	 ,	O
although  	although  	 IN	O
not  	not  	 RB	O
licensed  	licensed  	 VBN	O
for  	for  	 IN	O
use  	use  	 NN	O
in  	in  	 IN	O
pregnancy 	pregnancy 	 NN	O
,  	,  	 ,	O
raltegravir  	raltegravir  	 NNS	B-NP
may  	may  	 MD	O
need  	need  	 VB	O
to  	to  	 TO	O
be  	be  	 VB	O
considered  	considered  	 VBN	O
in  	in  	 IN	O
some  	some  	 DT	O
pregnant  	pregnant  	 JJ	O
women  	women  	 NNS	O
with  	with  	 IN	O
antiretroviral  	antiretroviral  	 JJ	B-NP
resistance  	resistance  	 NN	I-NP
or  	or  	 CC	O
tolerability  	tolerability  	 JJ	B-NP
issues  	issues  	 NNS	I-NP
with  	with  	 IN	O
current  	current  	 JJ	O
HAART  	HAART  	 NNP	B-NP
regimens 	regimens 	 NN	I-NP
.  	.  	 .	O
